Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in Non-V600E BRAF-Mutated Melanoma
NCT01586195Phase 2Terminated
- Sponsor
- Genentech
- Start
- Oct 2011
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in melanoma, sponsored by Genentech. Primary endpoint: Best Objective Response Rate at 42 months. Started Oct 2011; status: terminated.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01586195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01586195.